CVRS - Corindus Vascular Robotics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.0500
-0.0300 (-1.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0800
Open2.0800
Bid2.0600 x 1800
Ask2.0900 x 800
Day's Range2.0000 - 2.0800
52 Week Range0.7000 - 2.5350
Volume540,822
Avg. Volume1,108,796
Market Cap422.759M
Beta (3Y Monthly)2.47
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire3 days ago

    Corindus Announces First Robotic-Assisted Interventions in Japan for CorPath GRX Post-Market Study

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that the first clinical robotic-assisted PCI procedures in Japan were completed in partnership with Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital. CorPath GRX received Pharmaceutical and Medical Device Agency (PMDA) approval in 2018 and A1 technical fee reimbursement for Japan in March of this year.

  • Business Wire20 days ago

    Corindus Vascular Robotics Files Required Registration Statement for Holders of Recently Completed $19.8 Million Private Placement

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it filed a registration statement on behalf of investors that participated in its recently completed private placement. As previously disclosed, earlier this quarter, Corindus sold shares of its common stock to a large institutional investor and certain existing stockholders with contractual preemptive rights, including Hudson Executive Capital (“HEC”) and BioStar Ventures, for aggregate gross proceeds of approximately $19.8 million. HEC purchased an amount in excess of their allotment under the preemptive rights.

  • Business Wirelast month

    Corindus Reports Fourth Quarter and Full Year 2018 Results

    Submitted Neurovascular Indication Marking Important Step toward Addressing Stroke Market; Raised $19.8 Million to Fund Ongoing Innovation

  • Business Wirelast month

    Corindus Vascular Robotics Announces Additional Closing of Private Placement

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced the execution of an additional closing of the private placement previously announced on February 26, 2019. In the additional closing, existing investors with preemptive rights purchased an aggregate of 3,512,124 shares of the Company’s common stock on the same terms and at the same price of $1.3796 per share as the initial closing through the exercise of such preemptive rights and the purchase of certain additional shares. The Company intends to use the proceeds for general corporate purposes.

  • Business Wirelast month

    Corindus to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced that it will release fourth quarter and full year 2018 financial and business results on Tuesday, March 12, 2019 after the close of the U.S.

  • Business Wirelast month

    Corindus to Present at 39th Annual Cowen Health Care Conference on March 13, 2019

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer,

  • Business Wire2 months ago

    Corindus Vascular Robotics Announces Closing of Private Placement for $15 Million

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American:CVRS), a leading developer of precision vascular robotics, today announced the execution of a private placement transaction with a large institutional investor pursuant to which it will sell and issue an aggregate of 10,872,716 shares of its common stock, at a purchase price of $1.3796 per share, resulting in aggregate gross proceeds to the Company of approximately $15 million, which the Company expects to receive during the day. The Company intends to use the proceeds for general corporate purposes. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state and other jurisdiction.

  • Business Wire2 months ago

    Corindus Announces FDA Submission for Neurovascular Intervention Indication for CorPath® GRX Vascular Robotic System

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use the CorPath GRX System in neurovascular intervention. Upon successful FDA clearance, CorPath GRX would become the world’s first and only robotic platform indicated for use in PCI, PVI and neurovascular intervention (NVI).

  • Business Wire4 months ago

    Corindus’ Technology Successfully Used in World’s First-in-Human Telerobotic Coronary Intervention

    CorPath® telerobotic interventional platform has the potential to deliver timely, specialized cardiovascular treatment to remote, underserved patient populations across the globe. Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announces that its CorPath technology was used to conduct the first-in-human (FIH) Telerobotic Intervention Study, December 4 and 5, 2018, in India.

  • GlobeNewswire5 months ago

    Consolidated Research: 2018 Summary Expectations for Kadmon, Overstock, AECOM, Steelcase, CorMedix, and Corindus Vascular Robotics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire5 months ago

    Corindus to Present at Upcoming 2018 Healthcare Conferences

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced today that management will present at two investor conferences

  • Business Wire5 months ago

    Corindus Reports Third Quarter 2018 Results

    Advancing Development Programs for Remote Robotics and Neurovascular Applications

  • Business Wire6 months ago

    Corindus to Report Third Quarter Financial Results on November 6, 2018

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced that it will release financial and business results for the third quarter of 2018 on Tuesday, November 6, 2018 after the close of the U.S.

  • Business Wire7 months ago

    Corindus Technology Successfully used in Multiple Live Complex Robotic-Assisted Coronary Interventions at Transcatheter Cardiovascular Therapeutics 2018

    Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that its CorPath GRX System was used for multiple complex robotic-assisted percutaneous coronary interventions (PCI) at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference. In the first case at University of Washington Medical Center, Dr. William Lombardi, a high volume chronic total occlusion (CTO) PCI operator, performed the first live transmission of a hybrid CTO PCI using both manual and robotic techniques to successfully treat a patient suffering from a complete coronary artery blockage.

  • Business Wire7 months ago

    Corindus Announces First Live Transmission of Remote Robotic Demonstration Performed at Transcatheter Cardiovascular Therapeutics 2018 Conference

    Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced the first live transmission of a remote interventional procedure using the company’s CorPath® platform was performed at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Diego, CA on September 22, 2018. The remote interventional procedure was broadcast live from Mayo Clinic to the TCT Main Arena. Utilizing CorPath GRX with developmental remote technology, combined with a telecommunications system to enable communication with the bedside staff, the operator at Mayo Clinic had the ability to remotely manipulate interventional devices within a porcine model's arteries while located in a different building.

  • Business Wire7 months ago

    Corindus to Present at Ladenburg Thalmann 2018 Healthcare Conference

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer,

  • Business Wire7 months ago

    Corindus to Feature the CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics 2018 Conference

    Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, will feature its CorPath® GRX System at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference, September 21 – 25, in San Diego, CA. Corindus' CorPath GRX is the first FDA-cleared medical device for robotic-assisted vascular interventions.

  • Business Wire8 months ago

    Corindus to Present at 13th Annual Wells Fargo Securities Healthcare Conference

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the 13th Annual Wells Fargo Securities Healthcare Conference.

  • Business Wire8 months ago

    Corindus Reports Second Quarter 2018 Results

    Advancing Development Programs for Remote Robotics and Neurovascular Applications

  • Business Wire8 months ago

    Corindus to Showcase CorPath GRX® System for Peripheral Vascular Interventions at the 2018 Amputation Prevention Symposium

    Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that the CorPath GRX System will be showcased for peripheral applications at the 2018 Amputation Prevention Symposium in Chicago, IL. Jihad Mustapha, M.D., Interventional Cardiologist and AMP course director, will moderate an educational session entitled "Robotic Utilization in CLI in 2018: Protect Your Staff, Protect Yourself" on Friday, August 10th at 4:00 p.m. CT. During this session, Dr. Mustapha will share and discuss a previously taped procedure in which he used the CorPath GRX System during a robotic-assisted critical limb ischemia (CLI) case he performed at the first U.S. outpatient CLI center, the Advanced Cardiac & Vascular Amputation Prevention Center in Grand Rapids, MI, which was opened by Dr. Mustapha and Dr. Fadi Saab in February 2018.

  • Business Wire8 months ago

    Corindus to Report Second Quarter Financial Results on August 7, 2018

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced that it will release financial and business results for the second quarter of 2018 after the close of trading on Tuesday, August 7, 2018.

  • Business Wire8 months ago

    Corindus to Present at Canaccord Genuity 38th Annual Growth Conference

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, announced the company plans to participate in the 38th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.

  • ACCESSWIRE9 months ago

    Free Stock Performance Review on Boston Scientific and Three Additional Medical Equipment Stocks

    WallStEquities.com follows AxoGen Inc. (NASDAQ: AXGN), Boston Scientific Corp. (NYSE: BSX), Corindus Vascular Robotics Inc. (NYSE American: CVRS), and Edwards Lifesciences Corp. (NYSE: EW). Companies in the Medical Appliances and Equipment space are engaged in the manufacture of medical instruments, such as dental and surgical appliances.